Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Plague Vaccine Development: Current Research and Future Trends.

Verma SK, Tuteja U.

Front Immunol. 2016 Dec 14;7:602. doi: 10.3389/fimmu.2016.00602. eCollection 2016. Review.

2.

Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent.

Graham VA, Hatch GJ, Bewley KR, Steeds K, Lansley A, Bate SR, Funnell SG.

J Immunol Res. 2014;2014:807564. doi: 10.1155/2014/807564. Epub 2014 Jul 6.

3.

Protecting against plague: towards a next-generation vaccine.

Williamson ED, Oyston PC.

Clin Exp Immunol. 2013 Apr;172(1):1-8. doi: 10.1111/cei.12044. Review.

4.

Kinetics of innate immune response to Yersinia pestis after intradermal infection in a mouse model.

Bosio CF, Jarrett CO, Gardner D, Hinnebusch BJ.

Infect Immun. 2012 Nov;80(11):4034-45. doi: 10.1128/IAI.00606-12. Epub 2012 Sep 10.

5.

Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T.

Br J Pharmacol. 2010 Oct;161(4):721-48. doi: 10.1111/j.1476-5381.2010.00939.x. Review.

6.

TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.

Lin JS, Park S, Adamovicz JJ, Hill J, Bliska JB, Cote CK, Perlin DS, Amemiya K, Smiley ST.

Vaccine. 2010 Dec 16;29(2):357-62. doi: 10.1016/j.vaccine.2010.08.099. Epub 2010 Sep 15.

7.

Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice.

Wang Z, Zhou L, Qi Z, Zhang Q, Dai R, Yang Y, Cui B, Wang H, Yang R, Wang X.

Clin Vaccine Immunol. 2010 Jan;17(1):199-201. doi: 10.1128/CVI.00305-09. Epub 2009 Nov 25.

8.

Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Thomas RJ, Webber D, Collinge A, Stagg AJ, Bailey SC, Nunez A, Gates A, Jayasekera PN, Taylor RR, Eley S, Titball RW.

Infect Immun. 2009 Apr;77(4):1315-23. doi: 10.1128/IAI.01473-08. Epub 2009 Feb 2.

9.

Immune defense against pneumonic plague.

Smiley ST.

Immunol Rev. 2008 Oct;225:256-71. doi: 10.1111/j.1600-065X.2008.00674.x. Review.

10.

Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.

Airhart CL, Rohde HN, Hovde CJ, Bohach GA, Deobald CF, Lee SS, Minnich SA.

Vaccine. 2008 Oct 16;26(44):5554-61. doi: 10.1016/j.vaccine.2008.08.007. Epub 2008 Aug 21.

11.

An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Stacy S, Pasquali A, Sexton VL, Cantwell AM, Kraig E, Dube PH.

J Immunol. 2008 Jul 1;181(1):109-15.

12.

Current challenges in the development of vaccines for pneumonic plague.

Smiley ST.

Expert Rev Vaccines. 2008 Mar;7(2):209-21. doi: 10.1586/14760584.7.2.209. Review.

13.

Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine.

Bubeck SS, Dube PH.

Clin Vaccine Immunol. 2007 Sep;14(9):1235-8. Epub 2007 Jul 25.

14.

Current trends in plague research: from genomics to virulence.

Huang XZ, Nikolich MP, Lindler LE.

Clin Med Res. 2006 Sep;4(3):189-99. Review.

15.

Mice naturally resistant to Yersinia pestis Delta pgm strains commonly used in pathogenicity studies.

Congleton YH, Wulff CR, Kerschen EJ, Straley SC.

Infect Immun. 2006 Nov;74(11):6501-4. Epub 2006 Sep 5.

16.

Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, Jabri B, Schneewind O.

Infect Immun. 2006 Aug;74(8):4910-4.

17.

Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system.

Santi L, Giritch A, Roy CJ, Marillonnet S, Klimyuk V, Gleba Y, Webb R, Arntzen CJ, Mason HS.

Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):861-6. Epub 2006 Jan 12.

18.

Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M.

Infect Immun. 2005 Jun;73(6):3598-608.

19.

Kinetics of disease progression and host response in a rat model of bubonic plague.

Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ.

Am J Pathol. 2005 May;166(5):1427-39.

20.

Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague.

Jarrett CO, Sebbane F, Adamovicz JJ, Andrews GP, Hinnebusch BJ.

Infect Immun. 2004 Apr;72(4):2052-6.

Supplemental Content

Support Center